If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Saxagliptin Plus Metformin or Glyburide Significantly Improve Glycaemic Control in Type 2 Diabetes: Presented at EASD By Bruce Sylvester VIENNA, Austria -- October 4, 2009 -- Saxagliptin plus metformin or glyburide significantly improves glycaemic control in patients with type 2 diabetes, researchers stated here at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD). “All saxagliptin groups achieved a statistically significant decrease in haemoglobin [Hb] A1C,” said presenter and lead investigator, Roland Chen, MD, Bristol-Myers Squibb, Princeton, New Jersey, on October 1. Dr. Chen and colleagues conducted an analysis of 3 multicentre, randomised, double-blind, 24-week, phase 3 trials evaluating efficacy and safety of saxagliptin as add-on to metformin therapy or initial combination therapy, as well as saxagliptin as add-on to glyburide. In the study evaluating saxagliptin as add-on therapy to metformin, 743 patients who were adequately controlled on metformin were randomised to metformin plus saxagliptin or metformin plus placebo. In the combination study, 1,306 drug-naïve patients were randomised to saxagliptin plus metformin, saxagliptin plus placebo, or metformin plus placebo. The third study analysed included 768 patients inadequately controlled on glyburide alone to saxagliptin or uptitrated glyburide plus placebo in addition to open-label glyburide. The study allowed for blinded titration in the glyburide plus placebo arm (up to 15 mg daily). At 24 weeks, patients treated with saxagliptin plus metformin, regardless of whether it was add-on or initial combination therapy, and patients treated with saxagliptin plus glyburide achieved statistically significantly greater decreases from baseline in Hb A1C, compared with control patients (P < .0001; P < .0002; P = .0117, respectively). In addition, twice as many patients treated with saxagliptin plus metformin or glyburide achieved Hb A1C goals of <7% and <=6.5%, respectively, compared with control patients. Funding for this study was provided by Bristol-Myers Squibb. [Presentation title: Reaching HbA1c Goals With Saxagliptin in Combination With Metformin or Sulfonylurea. Abstract 753]
|
